Design Therapeutics (DSGN) Stock Forecast: StockMap's 2-Week Call
DSGN stock forecast: StockMap's model makes no two-week call on Design Therapeutics after the Nov 19 close: its evidence is split, 3 reasons for and 12 against. Too few two-week windows graded to judge yet.
Design Therapeutics last closed at $9.32, -1.58% on the session.
Against the IVW growth benchmark the position is +0.75% over the forecast window.
Design Therapeutics' market cap is $596.84M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -8 (too close to call).
Where DSGN sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
3 daily calls for DSGN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Design Therapeutics in the 22nd percentile on return on equity, where 100 is best.
Design Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Design Therapeutics as the 159th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Design Therapeutics ranks 98th of 394 in the group, against a group median of -0.27.